Jubilant Therapeutics’ JBI-778 Granted Orphan Drug Designation by US FDA for Glioblastoma Multiforme Treatment
Jubilant Therapeutics, a clinical-stage biopharmaceutical company, has announced that JBI-778, an oral PRMT5 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration ...